TheEdgeResearch
Home / Stocks / WUXIF

WuXi AppTec Co., Ltd. (WUXIF)

OTC Healthcare Medical - Diagnostics & Research
$23.77 ▼ -5.13%
Market Cap
$65.44B
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Beta
0.49
52-Wk Range
13.6-29.1
CEO
Ge Li
Country
CN
Currency
USD

WuXi AppTec Co., Ltd. operates in the Medical - Diagnostics & Research industry of the Healthcare sector, headquartered in Shanghai, SH, CN. The stock last traded at $23.77, down 5.13% on the session, giving a market capitalisation of $65.44B. On trailing twelve-month figures it carries a trailing P/E of 15.34, a net margin of 45.5%. Its beta of 0.49 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
15.34
Price / Sales
7.35
Price / Book
4.23
EV / EBITDA
12.63
Gross margin
53.2%
Operating margin
43.0%
Net margin
45.5%
Return on equity
—
Debt / equity
0.09
Current ratio
3.43
Dividend yield
1.5%
Payout ratio
27.6%
Company profile
Exchange
Other OTC
Employees
33,834
IPO date
2020-03-17
Headquarters
Shanghai, SH, CN
About WuXi AppTec Co., Ltd.

WuXi AppTec Co., Ltd., an investment holding company, provides research and manufacturing services to discover, develop, and manufacture spectrum for small molecule drugs in the People’s Republic of China, the United States, Europe, and internationally. The company operates through WuXi Chemistry, WuXi Testing, WuXi Biology, and Others segments. It offers contract research, development, and manufacturing organization (CDRMO) services for new drug development from discovery to commercial covering various categories for various synthetic molecular modalities, including small molecules, oligonucleotides, peptides, and complex conjugates; and biology services and solutions which support stand-alone and integrated projects from target discovery to candidate selection and into the clinic. The company also provides laboratory testing services, such as toxicology, DMPK, and bioanalytical services; clinical contract research organization services, including Phase I to Phase IV clinical development services, and bioequivalence for products including pharmaceuticals and biologics; and site management organization, patient recruitment, site start-up, and academic research organization. In addition, it offers services for biology; CDRMO platform for small molecules, oligonucleotides, and peptides; drug research and development testing; and clinical research services. WuXi AppTec Co., Ltd. was founded in 2000 and is headquartered in Shanghai, the People’s Republic of China.

Comparable companies

WuXi AppTec Co., Ltd. is most often compared with the following Healthcare names:

CRLIQVMEDP
More research on WUXIF
WUXIF technical analysis WUXIF TheEdge Score Compare against peers
Open full interactive analysis & DCF →